Elixir Medical's Peripheral Drug-Eluting Stent PMCF Study Successfully Launches First European Site with Support from Elixir Medical

May 29,MDCE CROMedical Expertise Supporting an Innovative Medical Device CompanyPeripheral Drug-Eluting StentSuccessfully Held at a Research Center in PolandSite Initiation Visit (SIV）. The project was officially launched in the first half of 2025, with plans to complete 153 post-market clinical follow-up (PMCF) cases at five leading research centers in Poland, dedicated to collecting high-quality clinical data to meet European regulatory requirements, in order toObtaining Product Renewal and Future Continuous MarketMarket Access. Previously, the projectFor use onlyObtained national ethical approval within two months. The successful conduct of the Site Initiation Visit (SIV) at this center verified that the investigators are fully qualified, have a thorough understanding of the protocol, and that all study materials are in place, confirming full readiness to commence the trial. This marks the launch of this European Post-Market Clinical Follow-up (PMCF) projectOfficially commenced operations and entered the patient recruitment preparation phase, forProduct in EuropeContinuation of Compliance in the Asian Market, Expanding International Reputation and Sustained Volume GrowthLaid a solid foundation。

In advancing the European PMCF study project for peripheral drug-eluting stents, MDCE CRO has undoubtedly emerged as the core driving force and key engine behind the project’s success. Leveraging its profound professional expertise and exceptional local execution capabilities, MDCE CRO has not only provided the sponsor with comprehensive, customized services throughout the entire project lifecycle but also demonstrated irreplaceable value and contributions at every critical stage.

The MDCE CRO project team was deeply involved in protocol revisions to ensure scientific rigor and operational feasibility. Meanwhile, based on the sponsor-provided checklist, the team conducted comprehensive due diligence on research centers and Principal Investigators (PIs), accurately assessing each center’s clinical team capabilities, budget frameworks, and patient recruitment potential, thereby laying the foundation for the rapid selection of high-quality centers and the advancement of collaborations. In the preparation and submission of ethical documentation, MDCE CRO demonstrated its extensive project experience and profound professional expertise. Through efficient team collaboration and refined management, MDCE CRO completed the preparation and submission of all necessary documents within just two months, successfully obtaining national ethical approval. This significantly reduced the projected time costs and secured valuable time for the project’s rapid advancement.

Following the successful finalization of the collaboration with the first site, MDCE CRO efficiently organized and prepared for the site initiation visit. The meeting was attended by the Principal Investigator (PI), research nurses, MDCE CRO’s local Clinical Research Associate (CRA) in Poland, and the Sponsor’s Vice President of International Marketing. The discussions focused on in-depth protocol training, optimization of enrollment strategies, and standardized material management, ensuring a high-standard, compliant launch of the site and establishing a replicable model for other centers. With the comprehensive readiness of the site’s personnel and materials, the project has officially entered the recruitment and enrollment phase, marking a new stage of substantive implementation.

The successful advancement of this Post-Market Clinical Follow-up (PMCF) study has established solid strategic value and broad prospects for this innovative medical device company in the European market. It not only ensures that the product complies with the latest European Medical Device Regulation (MDR) requirements, thereby facilitating certificate renewal and safeguarding its continued legal sale in Europe, but also consolidates and expands long-term strategic partnerships with key opinion leaders (KOLs) in the field through deep collaboration with top-tier European clinical research centers. The large-scale PMCF data generated by the project will robustly validate the long-term safety and efficacy of the product in the European population, providing strong evidence-based medical support. This will significantly enhance the product’s international reputation and market competitiveness, injecting powerful momentum into the company’s sustained volume growth in overseas markets and its global commercialization strategy.

MDCE CRO will continue to empower clients with professional, efficient, and customized end-to-end services, enabling them to gain a competitive edge in the complex international regulatory landscape. Together, we will advance the globalization of innovative medical devices, bringing exceptional medical achievements to the world and contributing to global health.

For inquiries regarding overseas clinical trials and regulatory affairs, please scan the QR code to submit your information or contact us via the following methods:

Tel: +86 18611648819

Email: ask@mdcecro.com